Skip NavigationSkip to Content

Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells

  1. Author:
    Kubo, Satoshi [ORCID]
    Kataria, Rhea
    Yao, Yikun [ORCID]
    Gabrielski, Justin Q
    Zheng, Lixin
    Markowitz,Tovah
    Chan, Waipan
    Song, Jian
    Boddapati, Arun K [ORCID]
    Saeki, Keita [ORCID]
    Häupl, Björn
    Park, Ann Y
    Cheng, Yan H
    Cui, Jing
    Oellerich, Thomas
    Lenardo, Michael J [ORCID]
  2. Author Address

    Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., National Institute of Allergy and Infectious Diseases Collaborative Bioinformatics Resource, Frederick National Laboratory for Cancer Research Leidos Biomedical Research, Inc., Frederick, MD 21702., Axle Informatics, Bethesda, MD 20892., Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Division of Developmental Biology, National Institute of Child Health and Human Development, Bethesda, MD 20892., Department of Medicine II, Hematology/Oncology, Goethe University, 60590 Frankfurt am Main, Germany., German Cancer Consortium/German Cancer Research Center, 69120 Heidelberg, Germany., Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt am Main, Germany.,
    1. Year: 2022
    2. Date: Aug 16
    3. Epub Date: 2022 08 08
  1. Journal: Proceedings of the National Academy of Sciences of the United States of America
    1. 119
    2. 33
    3. Pages: e2208522119
  2. Type of Article: Article
  3. Article Number: e2208522119
  1. Abstract:

    Apoptosis is a genetically regulated program of cell death that plays a key role in immune disease processes. We identified EBF4, a little-studied member of the early B cell factor (EBF) family of transcription factors, in a whole-genome CRISPR screen for regulators of Fas/APO-1/CD95-mediated T cell death. Loss of EBF4 increases the half-life of the c-FLIP protein, and its presence in the Fas signaling complex impairs caspase-8 cleavage and apoptosis. Transcriptome analysis revealed that EBF4 regulates molecules such as TBX21, EOMES, granzyme, and perforin that are important for human natural killer (NK) and CD8+ T cell functions. Proximity-dependent biotin identification (Bio-ID) mass spectrometry analyses showed EBF4 binding to STAT3, STAT5, and MAP kinase 3 and a strong pathway relationship to interleukin-2 regulated genes, which are known to govern cytotoxicity pathways. Chromatin immunoprecipitation and DNA sequencing analysis defined a canonical EBF4 binding motif, 5 39;-CCCNNGG/AG-3 39;, closely related to the EBF1 binding site; using a luciferase-based reporter, we found a dose-dependent transcriptional response of this motif to EBF4. We also conducted assay for transposase-accessible chromatin sequencing in EBF4-overexpressing cells and found increased chromatin accessibility upstream of granzyme and perforin and in topologically associated domains in human lymphocytes. Finally, we discovered that the EBF4 has basal expression in human but not mouse NK cells and CD8+ T cells and vanishes following activating stimulation. Together, our data reveal key features of a previously unknown transcriptional regulator of human cytotoxic immune function.

    See More

External Sources

  1. DOI: 10.1073/pnas.2208522119
  2. PMID: 35939714

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel